Chengdu Kanghua Biological Stock Current Valuation
| 300841 Stock | 57.69 0.06 0.10% |
Valuation analysis of Chengdu Kanghua Biol helps investors to measure Chengdu Kanghua's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Chengdu Kanghua's Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Total Cash From Operating Activities is expected to grow to about 602.7 M, whereas Cash is forecasted to decline to about 573.3 M. Fundamental drivers impacting Chengdu Kanghua's valuation include:
Price Book 2.2485 | Enterprise Value 7.2 B | Enterprise Value Ebitda 11.3979 | Price Sales 4.6939 | Trailing PE 13.9417 |
Overvalued
Today
Please note that Chengdu Kanghua's price fluctuation is very steady at this time. Calculation of the real value of Chengdu Kanghua Biol is based on 3 months time horizon. Increasing Chengdu Kanghua's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Chengdu Kanghua is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Chengdu Stock. However, Chengdu Kanghua's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 57.69 | Real 50.06 | Hype 57.69 | Naive 55.32 |
The real value of Chengdu Stock, also known as its intrinsic value, is the underlying worth of Chengdu Kanghua Biol Company, which is reflected in its stock price. It is based on Chengdu Kanghua's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Chengdu Kanghua's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Chengdu Kanghua Biological helps investors to forecast how Chengdu stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Chengdu Kanghua more accurately as focusing exclusively on Chengdu Kanghua's fundamentals will not take into account other important factors: Chengdu Kanghua Biological Company Current Valuation Analysis
Chengdu Kanghua's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Chengdu Kanghua Current Valuation | 7.22 B |
Most of Chengdu Kanghua's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Chengdu Kanghua Biological is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Chengdu Kanghua Biological has a Current Valuation of 7.22 B. This is 49.72% lower than that of the Biotechnology sector and 55.47% higher than that of the Health Care industry. The current valuation for all China stocks is 56.56% higher than that of the company.
Chengdu Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chengdu Kanghua's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Chengdu Kanghua could also be used in its relative valuation, which is a method of valuing Chengdu Kanghua by comparing valuation metrics of similar companies.Chengdu Kanghua is currently under evaluation in current valuation category among its peers.
Chengdu Fundamentals
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.33 % | ||||
| Operating Margin | 0.36 % | ||||
| Current Valuation | 7.22 B | ||||
| Shares Outstanding | 134.65 M | ||||
| Shares Owned By Insiders | 35.34 % | ||||
| Shares Owned By Institutions | 20.05 % | ||||
| Price To Book | 2.25 X | ||||
| Price To Sales | 4.69 X | ||||
| Revenue | 1.58 B | ||||
| Gross Profit | 1.34 B | ||||
| EBITDA | 735.65 M | ||||
| Net Income | 509.22 M | ||||
| Total Debt | 190.91 M | ||||
| Book Value Per Share | 26.59 X | ||||
| Cash Flow From Operations | 573.98 M | ||||
| Earnings Per Share | 4.12 X | ||||
| Target Price | 75.18 | ||||
| Number Of Employees | 672 | ||||
| Beta | 2.46 | ||||
| Market Capitalization | 7.73 B | ||||
| Total Asset | 4.21 B | ||||
| Retained Earnings | 2.26 B | ||||
| Working Capital | 1.98 B | ||||
| Annual Yield | 0.03 % | ||||
| Net Asset | 4.21 B | ||||
| Last Dividend Paid | 2.0 |
About Chengdu Kanghua Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chengdu Kanghua Biological's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chengdu Kanghua using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chengdu Kanghua Biological based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Chengdu Stock
Chengdu Kanghua financial ratios help investors to determine whether Chengdu Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Chengdu with respect to the benefits of owning Chengdu Kanghua security.